Effect of chitosan nanoparticles on the inhibition of Candida spp. biofilm on denture base surface

Gondim, Brenna Louise Cavalcanti; Castellano, Lúcio Roberto Cançado; Castro, Ricardo Dias de; Machado, Giovanna; Carlo, Hugo Lemes; Valença, Ana Maria Gondim; Carvalho, Fabíola Galbiatti de

doi:10.1016/j.archoralbio.2018.07.004

Cited by 71 publications

(47 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ability to form a biofilm is an important virulence mechanism that microorganisms such as bacteria and fungi are able to build during infection, which is also associated with disease persistence as well as relapses (Wojtyczka et al, 2013 ; Sav et al, 2018 ). The antibiofilm activity of NPs has been studied and the potential of nanoformulations to disrupt these complex matrices have been reported (Khan et al, 2012 ; Gondim et al, 2018 ; Yang et al, 2019 ).…”

Section: Nps and The Development Of A New Therapeutic Approach And Vamentioning

confidence: 99%

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Kischkel

Rossi

Santos

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates remain unacceptably high. Moreover, antifungal therapy is expensive, treatment periods can range from weeks to years, and toxicity is also a serious concern. In recent years, the increased number of immunocompromised individuals has contributed to the high global incidence of systemic fungal infections. Given the high morbidity and mortality rates, the complexity of treatment strategies, drug toxicity, and the worldwide burden of disease, there is a need for new and efficient therapeutic means to combat invasive mycoses. One promising avenue that is actively being pursued is nanotechnology, to develop new antifungal therapies and efficient vaccines, since it allows for a targeted delivery of drugs and antigens, which can reduce toxicity and treatment costs. The goal of this review is to discuss studies using nanoparticles to develop new therapeutic options, including vaccination methods, to combat systemic mycoses caused by Candida sp., Cryptococcus sp., Paracoccidioides sp., Histoplasma sp., Coccidioides sp., and Aspergillus sp., in addition to providing important information on the use of different types of nanoparticles, nanocarriers and their corresponding mechanisms of action.

show abstract

Section: Nps and The Development Of A New Therapeutic Approach And Vamentioning

confidence: 99%

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Kischkel

Rossi

Santos

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…A recent study also showed that Ag nanoparticles have altered multiple cellular targets including ergosterol content, fatty acid composition, cell membrane integrity and ultrastructure [ 97 ]. Another biopolymer with promising anti-biofilm property is chitosan nanoparticles, which were demonstrated by a recent study to be effective in C. albicans biofilm inhibition on a resin denture surface [ 98 ]. Moreover, the efficacy of other nanoparticles namely gold nanoparticles [ 99 ], silica nanoparticles [ 100 ] and selenium nanoparticles either alone or as a carrier for antifungal drugs has also been explored [ 101 ].…”

Section: Future Directions Of Research On New Antifungal Drugs Tarmentioning

confidence: 99%

Transcriptomic and Genomic Approaches for Unravelling Candida albicans Biofilm Formation and Drug Resistance—An Update

Chong

Chin

Wong

et al. 2018

Genes

View full text Add to dashboard Cite

Candida albicans is an opportunistic fungal pathogen, which causes a plethora of superficial, as well as invasive, infections in humans. The ability of this fungus in switching from commensalism to active infection is attributed to its many virulence traits. Biofilm formation is a key process, which allows the fungus to adhere to and proliferate on medically implanted devices as well as host tissue and cause serious life-threatening infections. Biofilms are complex communities of filamentous and yeast cells surrounded by an extracellular matrix that confers an enhanced degree of resistance to antifungal drugs. Moreover, the extensive plasticity of the C. albicans genome has given this versatile fungus the added advantage of microevolution and adaptation to thrive within the unique environmental niches within the host. To combat these challenges in dealing with C. albicans infections, it is imperative that we target specifically the molecular pathways involved in biofilm formation as well as drug resistance. With the advent of the -omics era and whole genome sequencing platforms, novel pathways and genes involved in the pathogenesis of the fungus have been unraveled. Researchers have used a myriad of strategies including transcriptome analysis for C. albicans cells grown in different environments, whole genome sequencing of different strains, functional genomics approaches to identify critical regulatory genes, as well as comparative genomics analysis between C. albicans and its closely related, much less virulent relative, C. dubliniensis, in the quest to increase our understanding of the mechanisms underlying the success of C. albicans as a major fungal pathogen. This review attempts to summarize the most recent advancements in the field of biofilm and antifungal resistance research and offers suggestions for future directions in therapeutics development.

show abstract

“…For example, nanoglasses, chlorhexidine, chitosan, and metallic nanoparticles have been applied as antibacterial and antifungal additives [10]. Corresponding in vitro or in vivo trials showed differing effectiveness of these modifications, but none of these antimicrobial alterations has prevailed over the others or is actually widely used in dentistry [11][12][13][14][15]. The luting materials tested in the present study are zinc oxide phosphate cements (ZOP), representing the most common conventional luting material in dentistry [1].…”

Section: Introductionmentioning

confidence: 96%

The antimicrobial and cytotoxic effects of a copper-loaded zinc oxide phosphate cement

Wassmann¹,

Schubert²,

Malinski³

et al. 2020

Clin Oral Invest

View full text Add to dashboard Cite

Objectives Evidence about modifications of dental luting materials to minimize biological failure at the "marginal gap" between teeth and fixed prosthodontics is scarce. We compared a copper-modified (Co-ZOP) and a conventional zinc oxide phosphate cement (ZOP) in terms of antimicrobial and cytotoxic potentials in vitro and in vivo. Materials and methods Specimens of ZOP and Co-ZOP were characterized by the mean arithmetic roughness (Ra) and surface free energy (SFE). Powder components were examined using scanning electron microscopy (SEM). Energy-dispersive X-ray spectroscopy (EDX) showed elemental material compositions. In vitro microbial adhesion was shown using SEM, luminescence, and fluorescence assays. CCK-8 assays of mouse fibroblasts (L929) and human gingival fibroblasts (GF-1) were performed after 6, 24, and 48 h of specimen incubation. In vivo, ZOP and Co-ZOP specimens were applied intraorally for 12 h; biofilm accumulation was shown using SEM. Results Ra of ZOP and Co-ZOP showed no significant differences; SFE was significantly higher for Co-ZOP. EDX exhibited minor copper radiation for Co-ZOP, none for ZOP. In vitro fungal adhesion to Co-ZOP was significantly higher than to ZOP; in vitro streptococcal adhesion, cytotoxicity, and in vivo biofilm formation were not significantly different. Conclusions Co-ZOP showed low surface allocations of copper with no improved antimicrobial properties compared with conventional ZOP in vitro or in vivo. Clinical relevance Antimicrobial effects and low cytotoxicity of biomaterials are important for the clinical outcome. Based on our in vitro and in vivo results, no clinical recommendation can be given for the tested Co-ZOP.

show abstract

Effect of chitosan nanoparticles on the inhibition of Candida spp. biofilm on denture base surface

Cited by 71 publications

References 32 publications

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Transcriptomic and Genomic Approaches for Unravelling Candida albicans Biofilm Formation and Drug Resistance—An Update

The antimicrobial and cytotoxic effects of a copper-loaded zinc oxide phosphate cement

Contact Info

Product

Resources

About